Mechanism of action [ edit ] HER2 is an extracellular receptor—a receptor tyrosine kinase - that when activated, sets off signal transduction through several pathways that stimulate cell proliferation and cell growth; if overexpressed it can cause uncontrollable growth.

Mechanism of action. Human epidermal growth factor receptor-2 (HER2) is a tyrosine kinase receptor that plays an integral role in cell proliferation, differentiation, and survival.

Pertuzumab – Mode of Action and Rationale for Combination with Trastuzumab. Pertuzumab is a humanized monoclonal antibody that binds to the dimerization domain of HER2. Blocking the pairing of the most potent signaling HER dimer, HER2-HER3, affects key …

A thorough understanding of the molecular mechanisms underlying the action and synergism of trastuzumab and pertuzumab is essential for moving forward to achieve high efficacy in treating HER2-positive breast cancer.

Pertuzumab, a humanized monoclonal antibody to the HER2 receptor, represents a promising new anti-HER2 agent with a novel mechanism of action targeting the inhibition of HER2 dimerization. Nonclinical and clinical data to date indicate that ...

Mechanism of Action. Pertuzumab is a recombinant humanized monoclonal antibody which targets the extracellular human epidermal growth factor receptor 2 protein (HER2) dimerization domain. Inhibits HER2 dimerization and blocks HER downstream signaling halting cell growth and initiating apoptosis.

PERJETA binds to subdomain II of HER2 receptors and blocks its ligand-dependent hetrodimerization with HER1, HER3, and HER4. 1. PERJETA inhibits HER2:HER3 dimer formation and downstream signaling, suppressing HER2-mediated cell proliferation. It also augments antibody-dependent cell-mediated cytotoxicity (ADCC). 1,8-10.

Jan 25, 2017 · Mechanism of Action. Pertuzumab targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein (HER2) and, thereby, blocks ligand-dependent heterodimerization of HER2 with other HER family members, including EGFR, HER3, and HER4.

Oct 10, 2014 · Description/Mechanism of Action . Pertuzumab is a recombinant humanized monoclonal antibody that binds at the HER2 extracellular domain (subdomain II) of the human epidermal growth factor receptor 2 (HER2) protein. Binding at this site prevents HER2 from dimerizing with other ligand-activated HER receptors preventing ligand-

In preclinical models, PERJETA targeted a different subdomain on the HER2 receptor than trastuzumab, to block dimerization with HER1, HER3, and HER4 receptors and provide a dual blockade of HER2-driven signaling pathways.1-3. Hyaluronidase allows subcutaneous delivery of higher drug volumes.